Orthopedic Group Practice Compensation Models

Two orthopedic groups offering the same headline salary can produce wildly different actual paychecks — because of how they allocate overhead, credit call, and split ASC distributions. Understanding the compensation model is as important as understanding the buy-in price.

Why this matters more than the starting number

When you compare offers from private orthopedic groups, the number most surgeons focus on is the first-year guarantee or the quoted salary range. That number tells you almost nothing about long-term earnings. What actually determines your income is:

• Which compensation model the group uses (and how overhead is allocated within it)
• Whether call compensation counts toward or against your productivity allocation
• How ASC distributions interact with clinical comp — or whether they're tracked separately
• What the partnership track looks like: how long, at what comp percentage, and when the model switches

Two groups with identical wRVU conversion factors can produce annual comp differences of $150,000–$400,000 depending on practice model — primarily because one group's overhead pool allocates implant costs per-surgeon while the other pools them equally. For a spine surgeon doing high-implant cases, that distinction alone can be worth $200,000/year.

The five compensation models

1. Pure equal shares (net proceeds split)

The group pools all net collections, subtracts operating overhead, and divides the remainder equally among partners. Each partner takes an identical distribution regardless of production volume, subspecialty, or call burden.

When this works in your favor: You're a high-overhead subspecialist (spine, TJA) where implant costs run $5,000–$25,000+ per case. Equal overhead pooling means your implant costs are subsidized by your lower-overhead partners (sports medicine, hand surgery). Early-career partners with lower production benefit if the group's senior partners remain high-volume.

When this works against you: You're a high-volume, low-overhead surgeon (arthroscopy, hand) who will consistently produce more than group average. Your income is capped by the group's mean, not your personal productivity.

Red flag: Equal shares groups that add new partners rapidly are effectively diluting the distributions of existing surgeons. Ask how many partners have been added in the last 5 years and what production each new partner brought.

2. Pure productivity (wRVU or percentage of collections)

Each surgeon earns based entirely on their individual production — either as a conversion factor applied to wRVUs generated, or as a percentage of collections they personally produced minus individually attributed overhead.

wRVU-based: The group establishes a conversion factor ($/wRVU). A spine surgeon generating 8,500 wRVUs/year at a $55/wRVU conversion factor earns $467,500 in clinical comp before any bonus or ASC distributions. The wRVU Compensation Analyzer walks through this calculation with MGMA 2025 benchmark context.

Percentage-of-collections: Simpler conceptually but more exposed to payer mix and billing efficiency. If a new surgeon joins with different payer mix (more Medicaid, lower-reimbursed plans), the percentage model may pay them the same effective conversion factor as a partner with 90% commercial insurance — unless overhead is individually attributed.

When this works in your favor: You expect to produce above group average. High-volume sports medicine or hand surgeons with efficient case mix and high commercial payer concentration typically outperform in pure productivity models.

When this works against you: You have a high-implant subspecialty with expensive case mix. Every $20,000 spinal fusion implant that generates 25.70 wRVUs (about $1,400 in conversion factor comp at $55/wRVU) comes with individually attributed implant cost — so your net is much lower than the wRVU number implies unless the model explicitly uses gross wRVUs with pooled overhead.

3. Hybrid (base salary + productivity bonus)

Surgeons receive a guaranteed base salary — typically set at the 25th–50th percentile of MGMA specialty benchmarks — plus a productivity bonus for production above a threshold. The threshold is often set at the production level required to cover the base plus overhead allocation.

This is the most common structure for early-career associates before partnership. The base provides income predictability during ramp-up; the bonus aligns long-term incentives with production.

Key variables to scrutinize:

• What is the threshold production level before the bonus kicks in?
• What percentage of collections (or wRVU conversion factor) applies above the threshold?
• Is overhead attributed individually above threshold, or is the bonus paid as a clean percentage of the productivity overage?
• What happens if you're above-threshold in some quarters and below in others — is there annual true-up?

4. Modified equal shares (seniority or ownership-weighted)

A variation on equal shares where senior partners receive a higher percentage of the net distribution, justified as return on capital contributions, practice-building risk, or referral development. Junior partners earn a lower fractional share for the first 2–5 years, stepping up on a schedule.

This structure is common in groups that built their referral base and ASC equity over decades and consider the junior-partner discount an implicit buy-in payment for inheriting established infrastructure. It can be fair — but the total compensation impact should be modeled explicitly over the partnership track period.

Example: A 5-partner group where senior partners hold 1.2 shares and a new junior partner holds 0.8 shares means the junior partner earns approximately 13% less than proportional for their contribution — before accounting for any formal buy-in payment.

5. Partnership class / tier structure

The most complex model, common in larger groups with 8+ surgeons and substantial ASC equity. The group has defined classes of ownership (Class A, Class B; Senior Partner, Junior Partner; Voting Partner, Non-Voting Partner) with different compensation percentages, capital obligations, and distribution rights.

Class progression is usually time-based (3–7 years), production-based, or both. Each class transition may require an additional capital contribution.

The financial planning complexity here is significant: you need to model the income at each class level, the capital calls to advance, the distribution rights at each level (especially for ASC equity), and the governance rights that determine your voice on future decisions. The Partnership Agreement Guide covers the legal structure; this section covers the compensation implications.

The hidden variable: overhead allocation

Two groups with identical wRVU conversion factors can produce vastly different net income — because of how they handle overhead.

For spine surgeons at $875K MGMA 2025 median: the fully pooled vs. individually attributed choice on implant costs alone can represent $100,000–$250,000 in annual income difference, depending on case mix and group composition. Always ask: "How are implant costs and variable supplies allocated across surgeons?"

Call compensation: four ways groups handle it

Call burden is one of the most significant non-salary income levers in orthopedic group practice — and also one of the most contentiously structured. Groups handle it four ways:

1. Separate call stipend: A fixed dollar amount per night/weekend on call, paid in addition to clinical comp. Range: $500–$2,000/night depending on market and group, with higher rates in rural or high-trauma markets. This is the cleanest structure for financial planning.
2. Call productivity is yours: Cases you do while on call are credited to your individual productivity — but call nights are not directly compensated beyond that. Good for high-volume call surgeons; unfavorable if you take significant call in a low-volume hospital or trauma center.
3. Call production is pooled: Trauma and call cases go into the group pool, not your individual account. Equalizes the luck element of call volume but reduces incentive for call productivity.
4. No call compensation, no credit: Call is simply a partnership obligation, unpaid and uncredited. This is most common in older equal-shares practices where call was historically considered part of the shared burden. Increasingly unacceptable to new partners and often a point of renegotiation.

ASC distributions: almost always separate

For groups with ambulatory surgery center equity, distributions are almost always tracked separately from clinical compensation — and that's important for two reasons.

First, ASC distributions flow from a separate entity (the ASC LLC or partnership) and are governed by the operating agreement, not the clinical group's compensation structure. They're typically based on ownership percentage, not production. A surgeon who owns 12% of the ASC receives 12% of distributions regardless of how many cases they personally performed at the facility in that quarter.

Second, because ASC distributions are pass-through income (K-1), they're taxed differently and may be subject to 3.8% NIIT at your income level — which your financial advisor and CPA need to coordinate on. See the ASC Investment ROI Calculator for full distribution modeling.

The relevant question when evaluating a group isn't just "what percentage of ASC ownership does partnership buy me?" but "how are ASC distributions handled when a partner reduces their case volume, or when new partners are admitted?" The operating agreement answers this — the Partnership Agreement Guide covers the key provisions to examine.

Interactive: Model comparison calculator

Enter your estimated production parameters to see how your take-home clinical comp differs across the three most common models (equal shares, pure productivity, hybrid).

Partnership track: the financial transition that matters most

Associates in private orthopedic groups typically spend 2–4 years on a fixed salary or hybrid model before being offered partnership. The transition changes three things simultaneously:

1. Comp model shifts: Associate-track hybrid → partner-track equal shares or productivity. This can mean a $150,000–$300,000 jump in annual income if your production exceeds the associate guarantee, or a surprise if your new production-based comp is lower than expected.
2. Capital obligation activates: Partnership buy-in is typically $300,000–$800,000 for a mid-sized orthopedic group with ASC equity. This is financed over 3–7 years from distributions or out-of-pocket. See the Partnership Buy-In Analyzer for the full ROI model.
3. Distribution access expands: Partners typically receive full ASC distribution rights on the same schedule as capital contributions — which is where the most significant long-term wealth accumulation occurs.

The financially critical question is not "what will I make as a partner?" but "what will I make in the 18-month window straddling the associate-to-partner transition?" During this window: buy-in payments reduce net cash flow, the comp model changes in ways that may reduce gross income temporarily, and tax planning around the S-Corp/PC structure often needs to be reconfigured. Plan for this 18-month window 12 months in advance.

Questions to ask before accepting a group offer

1. What compensation model does the group use, and when was it last changed? A group that switched from equal shares to productivity 3 years ago has a political history worth understanding.
2. How is overhead allocated? Fully pooled, individually attributed, or hybrid? How are implant costs handled specifically for your subspecialty?
3. What happens to comp during associate ramp-up? Is there a guarantee period, and what triggers the step-down to production-based comp?
4. How is call compensated? Separate stipend, credited to productivity, pooled, or unpaid obligation?
5. What is the conversion factor, and how often is it reviewed? A conversion factor that hasn't been updated in 5 years may now be below market. Compare against the <$48/wRVU flag in the wRVU Analyzer.
6. What are the ASC distribution mechanics? What percentage does partnership buy you, what is the distribution frequency, and what happens to distributions if you reduce case volume?
7. Can I see 3 years of pro forma partner distributions? Historical distribution data (not projected) is the most reliable indicator of what partnership is actually worth.
8. What is the partnership track timeline, and is it guaranteed? Some groups have informal "we invite you when we're ready" tracks; others have binding criteria in the associate agreement. Know which you're getting.

Red flags in group compensation structures

• No written compensation methodology: If the group can't point you to a document that explains how comp is calculated, the methodology can be changed unilaterally after you join.
• Call obligation unaddressed in the associate agreement: Groups that handle call as an informal obligation often have the most conflict about it. Get it in writing.
• Overhead allocation method changes frequently: Volatility in overhead methodology is usually a sign of internal conflict between high-overhead and low-overhead subspecialists. Ask why it changed last time.
• ASC distributions "included" in clinical comp: They should be tracked separately. If a group combines them to inflate the quoted comp number, you can't evaluate the practice investment independently.
• Equal shares with rapid expansion plans: A group planning to add 3 new partners in 2 years will dilute your distributions by 25–30% unless those new partners bring equivalent production. Model the dilution math explicitly.

How a fee-only advisor helps

Financial advisors who work with orthopedic surgeons routinely evaluate group compensation structures as part of the joining decision. A good advisor will:

• Model your expected comp under the actual methodology — not the quoted headline number — and compare it against MGMA benchmarks for your subspecialty and market
• Analyze the partnership buy-in ROI including both clinical comp and ASC distribution projections, discounted at an appropriate rate
• Coordinate with your employment attorney on what compensation provisions need to be in writing before you sign
• Configure your tax structure (S-Corp election, retirement account setup) for the specific income mix — W-2, K-1, and call stipends all have different planning implications

This analysis is most valuable before you sign, not after. Use the form below if you want to be matched with a fee-only advisor who works with orthopedic surgeons in private practice.

Related guides and calculators

• wRVU Compensation Analyzer — enter your production and conversion factor, get total comp estimate and MGMA 2025 percentile benchmark
• Partnership Buy-In Analyzer — model the break-even timeline and 10-year income advantage of the buy-in offer
• ASC Investment ROI Calculator — model ASC distributions, break-even, exit proceeds, and IRR on equity
• Ortho Total-Comp Calculator — compare hospital W-2 vs private partnership vs private + ASC over a 10-year horizon
• Contract Negotiation Guide — converting factor, guarantee periods, call compensation, ASC ownership rights, and red flags by employer type
• Partnership Agreement Guide — distribution waterfall, ownership classes, ASC equity mechanics, drag-along/ROFR provisions
• Subspecialty Lifetime Income Comparator — how your subspecialty choice shapes a 30-year income trajectory across practice settings

1. MGMA 2025 Physician Compensation and Production Survey — median and percentile benchmarks by specialty and practice model. Used for conversion factor market context on this page.
2. Medical Group Management Association, Understanding Physician Compensation Models. Overview of equal shares, productivity, and hybrid structures.
3. American Academy of Orthopaedic Surgeons (AAOS), Practice Management resources — group structure and compensation framework guidance for orthopedic practices.
4. Coker Group and VMG Health — physician practice valuation and compensation design surveys, regularly updated with specialty-level data on overhead allocation and call compensation trends.

Compensation model estimates and benchmarks reflect MGMA 2025 data and general market conditions as of June 2026. Actual group compensation depends on specific group methodology, payer mix, geographic market, and practice volume. This page does not constitute legal or financial advice.